Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases

BACKGROUND: FOXA1 expression is a good prognostic marker for endocrine therapy in hormone-positive breast cancer. We retrospectively examined breast cancer patients with luminal human epidermal growth factor receptor 2 (HER2)-negative tumours, as defined by immunohistochemistry, who received neo-adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Horimoto, Y, Arakawa, A, Harada-Shoji, N, Sonoue, H, Yoshida, Y, Himuro, T, Igari, F, Tokuda, E, Mamat, O, Tanabe, M, Hino, O, Saito, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453454/
https://www.ncbi.nlm.nih.gov/pubmed/25422910
http://dx.doi.org/10.1038/bjc.2014.595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453454/
https://www.ncbi.nlm.nih.gov/pubmed/25422910
http://dx.doi.org/10.1038/bjc.2014.595

Ejemplares similares